ResAppDx revenue has just started, if they are "gas" out then time for new management. No spin, the technology hasn't changed since you've invested in RAP many years ago. Their core products are still acute respiratory diagnosis and chronic respiratory management.
RAP Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held